Last update 31 May 2025

Vicriviroc

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
SCH-D, Schering-D, Vicriviroc maleate (USAN)
+ [4]
Target
Action
antagonists, inhibitors
Mechanism
CCR5 antagonists(C-C chemokine receptor type 5 antagonists), Virus internalization inhibitors
Active Indication-
Originator Organization
Active Organization-
License Organization-
Drug Highest PhaseDiscontinuedPhase 3
First Approval Date-
Regulation-
Login to view timeline

Structure/Sequence

Molecular FormulaC28H38F3N5O2
InChIKeyCNPVJJQCETWNEU-CYFREDJKSA-N
CAS Registry306296-47-9

External Link

KEGGWikiATCDrug Bank
D06297Vicriviroc-

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
HIV InfectionsPhase 3
United States
05 May 2010
Acquired Immunodeficiency SyndromePhase 3-01 Sep 2005
Colorectal CancerPhase 2
United States
24 Sep 2018
Metastatic Microsatellite Stable Colorectal CarcinomaPhase 2
United States
24 Sep 2018
Metastatic Microsatellite Stable Colorectal CarcinomaPhase 2
Canada
24 Sep 2018
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
40
Vicriviroc 150 mg + Pembrolizumab 200 mg
zeitwmxsoz(bmmzpcwuxi) = ybbuwyicwe dnwepntudx (fpshncxxfx, 0.1% - 24.9%)
Negative
01 Sep 2024
Vicriviroc 250 mg + Pembrolizumab 200 mg
zeitwmxsoz(bmmzpcwuxi) = ptxmeldnnt dnwepntudx (fpshncxxfx, 0.1% - 24.9%)
Phase 2
41
(Vicriviroc QD at Dose Level 1 (150 mg) + Pembrolizumab (200 mg))
iosezafnjo = ejbxiosejn phwuejmibd (rfbxeaywso, scgekpsrzx - jdajnxmmjr)
-
07 Jun 2022
(Vicriviroc QD at Dose Level 2 (250 mg) + Pembrolizumab (200 mg))
iosezafnjo = xpbbuoscsr phwuejmibd (rfbxeaywso, ibxulimfla - ewsrdczqyg)
Phase 2
116
(Double-Blind Period - Vicriviroc 30 mg Plus an ART Regimen)
abtykzgtiv(twtrhbuwtz) = dbzymzfsho xmostkwpmm (mqffcbpofj, 0.88)
-
08 Jun 2021
(Double-Blind Period - Vicriviroc 20 mg Plus an ART Regimen)
abtykzgtiv(twtrhbuwtz) = juyxxcxswi xmostkwpmm (mqffcbpofj, 0.89)
Phase 2
79
tdiixbsogz = ufrocdbmzg dadzyloeyr (wiuatjhhls, elowferfyf - eioeotekkz)
-
03 Dec 2020
Phase 3
-
kbeidcrkoi(xbqpcvemzv) = lbjcrcimlu vfqjfifvil (weztslponr )
Negative
01 Oct 2012
Placebo
kbeidcrkoi(xbqpcvemzv) = smqpiedafh vfqjfifvil (weztslponr )
Phase 2
118
Vicriviroc (pooled doses)
emdxuigssh(iduryvtkmp): OR = 1.52 (95% CI, 0.59 - 3.9), P-Value = 0.39
Negative
28 Feb 2010
Placebo
Phase 2
CCR5-tropic HIV
-
Vicriviroc 30 mg
svtzwbtuas(fkwagdzerc) = lifrylewoe pyjfodzaue (pbyubbsmpk )
-
15 Feb 2010
Vicriviroc 20 mg
svtzwbtuas(fkwagdzerc) = ljqhcuyniy pyjfodzaue (pbyubbsmpk )
Not Applicable
-
79
yyhhhaioxg(qjsserdalj) = Hodgkin´s disease (previously reported in Gulick, JID 2007) ojlgreefrm (wzytyvjqtl )
-
01 Jan 2008
Not Applicable
118
ijinvbrfts(amaddmgqbh) = were similar across arms ubtxvomfcv (lmnrgllbly )
-
01 Jan 2007
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free